Current controversies in bisphosphonate therapy

Orthopedics

Volumn 32, Issue 7, 2009, Pages 473-

  Kamath, Atul F ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ARTHROPLASTY; BONE CANCER; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE MINERAL; BONE PAIN; CALCIUM INTAKE; CALLUS; CEREBRAL PALSY; DIET SUPPLEMENTATION; DRUG APPROVAL; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; EXERCISE; EYE TOXICITY; FEMUR SUBTROCHANTERIC FRACTURE; FIBROUS DYSPLASIA; FOOD AND DRUG ADMINISTRATION; FRACTURE HEALING; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HYPERCALCEMIA; JAW OSTEONECROSIS; JOINT PROSTHESIS; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; NONHUMAN; OFF LABEL DRUG USE; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PAGET BONE DISEASE; RISK BENEFIT ANALYSIS; RISK REDUCTION; SINGLE DRUG DOSE; SKIN TOXICITY; STRESS FRACTURE; VITAMIN INTAKE;

ARTHRALGIA; DIPHOSPHONATES; DRUG ERUPTIONS; HUMANS; OSTEOLYSIS; OSTEONECROSIS; OSTEOPOROSIS;

EID: 70349190413     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20090527-03     Document Type: Editorial

References (37)

1. Parker-Pope T. Drugs to build bones may weaken them. http://www.nytimes. com/2008/07/15/health/15well.html?-r=1. Published July 15, 2008. Accessed February 20, 2009.
2. http://www.boston.com/business/healthcare/articles/2008/01/07/ fda-studies-pain-in-osteoperosis-drugs/. Accessed February 20, 2009.
3. http://www.washingtonpost.com/wp-dyn/content/article/2008/10/27/ AR2008102700763.html. Accessed February 20, 2009.
4. Morris CD, Einhorn TA. Bisphosphonates in orthopaedic surgery. J Bone Joint Surg Am. 2005;87(7):1609-1618.
5. Maclean C, Newberry S, Maglione M, et al. Systematic review - comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148(3):197-213. (Pubitemid 351665507)
6. Black DM, Delmas PD, Eastell R, et al; for HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-1822
7. Shanbhag AS. Use of bisphosphonates to improve the durability of total joint replacements. J Am Acad Orthop Surg. 2006; 14(4):215-225.
8. Johnson NK, Clifford T, Smith KM. Understanding risk factors, screening, and treatment of postmenopausal osteoporosis. Orthopedics. 2008;31(7). pii: orthosupersite.com/view.asp?rID=29794.
9. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357(20):2028-2039.
10. McClung MR, Lewiecki EM, Cohen SB; AMG 162 Bone Loss Study Group, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354(8):821-831.
11. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994; 9(5):745-751. (Pubitemid 24130477)
12. Lyles KW, Colón-Emeric CS, Magaziner JS, et al; for HORIZON Recurrent Fracture Trial. Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. N Engl J Med. 2007; 357:nihpa40967.
13. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD001155. (Pubitemid 351807494)
14. Wells GA, Cranney A, Peterson J, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD003376. (Pubitemid 351807542)
15. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; (1):CD004523. (Pubitemid 351824594)
16. Friedl G, Radl R, Stihsen C, Rehak P, Aigner R, Windhager R. The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J Bone Joint Surg Am. 2009; 91(2):274-281.
17. Shaw NJ, Boivin CM, Crabtree NJ. Intravenous pamidronate in juvenile osteoporosis. Arch Dis Child. 2000;83(2):143-145.
18. Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr. 2002; 141(5):644-651. (Pubitemid 35292762)
19. Liens D, Delmas PD, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet. 1994; 343(8903):953-954. (Pubitemid 24117233)
20. Chapurlat RD, Delmas PD, Liens D, Meunier PJ. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res. 1997; 12(10):1746-1752 (Pubitemid 27422377)
21. Lane JM, Khan SN, O'Connor WJ, et al. Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Relat Res. 2001; (382):6-12.
22. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998; 339(14):947-952 (Pubitemid 28455096)
23. Grewal VS, Fayans EP. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management. Todays FDA. 2008; 20(8):38-41, 43-46.
24. Sharma NS, Ooi JL, Masselos K, Hooper MJ, Francis IC. Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med. 200825; 359(13):1410-1411.
25. Belhadjali H, Slim R, Aouam K, Youssef M, Zili J. Cutaneous vasculitis induced by risedronate. Allergy. 2008;63(10):1405.
26. FDA Alert 1/7/2008. "Information on Bisphosphonates." http://www.fda.gov/cder/drug/infopage /bisphosphonates/default.htm. Accessed February 20, 2009.
27. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation [letter]. N Engl J Med 2007;356:1895-1896.
28. FDA. November 12, 2008 - Update to the October 1, 2007 Early Communication about the Ongoing Safety Review of Bisphosphonates. http://www.fda.gov/cder/drug/early-comm/bisphosphonates-update-200811.htm.
29. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of Alendronate and Risk of Incident Atrial Fibrillation in Women. Arch Intern Med. 2008; 168(8):826-831 (Pubitemid 351649266)
30. Sørensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008; 336(7648):813-816 (Pubitemid 351548223)
31. ACCP annual meeting proceedings. http://www.chestnet.org/about/press/ releases/2008/CHEST /PDF/OsteoporosisAtrialFib.pdf. Accessed February 20, 2009.
32. Majumdar SR. Oral bisphosphonates and atrial fibrillation. BMJ. 2008; 336(7648):784-785
33. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007; 89(3):349-353. (Pubitemid 46563912)
34. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008; 22(5):346-350. (Pubitemid 351630250)
35. Sayed-Noor AS, Sjödén GO. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy - a case report. Acta Orthop. 2008; 79(4):565-567.
36. Fleisch H. Can bisphosphonates be given to patients with fractures? J Bone Miner Res. 2001; 16(3):437-440.
37. Peter CP, Cook WO, Nunamaker DM, Provost MT, Seedor JG, Rodan GA. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res. 1996; 14(1):74-79.